OS Therapies

06/04/2026

OST-HER2 continues to advance as a potential treatment option for patients with recurrent, fully resected pulmonary metastatic osteosarcoma.

Updated data showed a 75% overall survival rate at 2.5 years compared to 47% pooled historical control (p=0.003), with no new patient deaths reported in the treated group since the previously reported two-year analysis. OS Therapies is incorporating these findings into regulatory submissions across multiple global markets as it pursues potential early market access pathways.

Read the full story from Investing.com: https://www.investing.com/news/stock-market-news/os-therapies-to-report-significant-survival-benefit-for-osther2-in-osteosarcoma-4721162

06/03/2026

The Jefferies Global Healthcare Conference is underway in New York City.

Members of the OS Therapies team are onsite this week, meeting with investors, biotech leaders, and potential partners during several days of discussions focused on innovation across healthcare and oncology.

We’re looking forward to a meaningful week of connecting with the broader biotech community throughout the conference.

06/02/2026

OST-HER2 continues to advance as a potential treatment option for patients with recurrent, fully resected pulmonary metastatic osteosarcoma.

Updated data showed a 75% overall survival rate at 2.5 years compared to 47% pooled historical control (p=0.003), with no new patient deaths reported in the treated group since the previously reported two-year analysis. OS Therapies is incorporating these findings into regulatory submissions across multiple global markets as it pursues potential early market access pathways.

Read the full story:

OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma

06/02/2026

OS Therapies (NYSE: OSTX) achieved statistically significant 2.5-year overall survival in its Phase 2b trial of OST-HER2 in fully resected pulmonary metastatic osteosarcoma.

At the 2.5-year timepoint, overall survival was 75% for OST-HER2 treated patients compared to 47% in pooled historical controls (p=0.003). They also reported no new patient deaths in the OST-HER2 treated group since the previously reported 2-year overall survival data.

Detailed data results are expected to be presented at the MIB Agents Osteosarcoma Conference later this month.

Read to learn more: https://bit.ly/49AhGfm

06/01/2026

Osteosarcoma remains one of the most common primary bone cancers affecting children and adolescents, with treatment approaches that have changed little over the past several decades.

OS Therapies is evaluating OST-HER2 in this setting, focusing on its Listeria-based platform and its interaction with HER2-expressing tumor cells. Through clinical research, the company is working to better understand how this immunotherapy approach performs and how it may be positioned within the current treatment landscape.

This work reflects a broader effort to explore new options in a disease area with significant unmet need.

Learn more: https://ostherapies.com/

05/30/2026

has begun in Chicago, and OS Therapies looks forward to taking part in the conversation alongside the global oncology community.

Over the coming days, researchers, clinicians and biotechnology companies will share new data, discuss emerging treatment strategies and explore the future of cancer care. Our team looks forward to engaging with colleagues and connecting with members of the oncology and osteosarcoma communities throughout the meeting.

We look forward to connecting!

05/29/2026

As begins today, OS Therapies (NYSE: OSTX) announced the publication of four articles related to OST-HER2 and osteosarcoma in Drug Discovery World.

The company also reiterated plans to release 2.5-year overall survival data from its Phase 2b clinical trial evaluating OST-HER2 in the prevention or delay of recurrence in fully resected pulmonary metastatic osteosarcoma during the 2026 ASCO Annual Meeting.

Read more: https://bit.ly/49YImXc

American Society of Clinical Oncology

05/28/2026

OS Therapies is looking forward to participating in the Jefferies Global Healthcare Conference, taking place June 3-5 in New York City.

As a New York-based company, we value the opportunity to engage with investors, partners, and members of the biotech community at one of healthcare’s leading industry conferences.

With continued advancement of OST-HER2 and broader development initiatives underway, we look forward to a productive week of meetings and discussion.

05/27/2026

OS Therapies looks forward to attending the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, one of the world’s leading gatherings for the oncology community.

Our team welcomes the opportunity to engage in discussions around osteosarcoma, immunotherapy development, and the future of cancer treatment innovation while connecting with colleagues, partners, investigators, and members of the oncology community throughout the meeting.

If you’ll be in Chicago for the conference this weekend, send us a message to connect.

05/26/2026

OS Therapies (NYSE: OSTX) is looking forward to attending several upcoming medical, financial, and scientific conferences, including:

• American Society of Clinical Oncology Annual Meeting | May 30 to June 3, 2026
• Jefferies Global Healthcare Conference | June 3 to 5, 2026
• Biotechnology Innovation Organization - BIO | June 16 to 19, 2026
• MIB Agents Osteosarcoma Alliance Factor Osteosarcoma Conference 2026 | June 25 to June 27, 2026

Learn more: https://bit.ly/4ut3wVz